Browsing ICR Divisions by author "Watts, Ellen"
Now showing items 1-2 of 2
-
Design and synthesis of dual kinase-bromodomain inhibitors targeting ALK and BRD4
Hoelder, S; Watts, E (Institute of Cancer Research (University Of London), 2019-12-31)Neuroblastoma is a paediatric cancer of neural crest origin and is the most common extracranial tumour in childhood. In high-risk patients with poor clinical outcome, mutations within the kinase domain of anaplastic lymphoma ... -
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.
Watts, E; Heidenreich, D; Tucker, E; Raab, M; Strebhardt, K; et al. (AMER CHEMICAL SOC, 2019-03)Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk ...